Login to Your Account

Clinic Roundup

Wednesday, October 26, 2011

• Apeptico GmbH, of Vienna, Austria, said AP301, an orally inhaled peptide for edematous respiratory failure, was well tolerated in a Phase I trial. A Phase IIa trial with an aerosol formulation is slated to begin next year.

• DelMar Pharmaceuticals Ltd., of Vancouver, British Columbia, initiated an open-label Phase I/II trial of VAL-083 for refractory glioblastoma multiforme. VAL-083 is a bi- functional alkylating agent approved in China for chronic myelogenous leukemia and solid tumors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription